Absci Corporation.(ABSI)

POST3.180.04+1.26%19:59 EDT

3.14+0.24+8.28%

CommunityCommunity
NewsNews
ProfileProfile
AnnouncementsAnnouncements

Company Profile
Company Name
Absci Corporation.
Market
NASDAQ
Establishment Date
- -
Employees
- -
Office Location
- -
Website
http://www.absci.com
Zip Code
- -
Phone
- -
Fax
- -
Introduction
Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit. It has a collaboration with Memorial Sloan Kettering Cancer Center to discover novel therapeutics using generative AI; with AstraZeneca PLC for AI-driven drug discovery against an oncology target; and with Twist Bioscience Corporation to design a novel therapeutic using generative AI. The company was founded in 2011 and is headquartered in Vancouver, Washington.
- 01-15
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 2024-11-14
  Beneficial Ownership Change
  Form SC 13G - Statement of Beneficial Ownership by Certain Investors
  Form SC 13G - Statement of Beneficial Ownership by Certain Investors
- 2024-11-12
  Quarterly Report
  Form 10-Q - Quarterly report [Sections 13 or 15(d)]
  Form 10-Q - Quarterly report [Sections 13 or 15(d)]
- 2024-11-12
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 2024-09-04
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 2024-08-14
  Quarterly Report
  Form 10-Q - Quarterly report [Sections 13 or 15(d)]
  Form 10-Q - Quarterly report [Sections 13 or 15(d)]
- 2024-08-14
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 2024-06-14
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 2024-06-13
  Proposed Sale Of Securities
  Form 144 - Report of proposed sale of securities
  Form 144 - Report of proposed sale of securities
- 2024-05-14
  Quarterly Report
  Form 10-Q - Quarterly report [Sections 13 or 15(d)]
  Form 10-Q - Quarterly report [Sections 13 or 15(d)]
- 2024-05-14
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 2024-03-21
  Employee Stock Ownership
  Form S-8 - Securities to be offered to employees in employee benefit plans
  Form S-8 - Securities to be offered to employees in employee benefit plans
- 2024-03-21
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 2024-03-21
  Annual Report
  Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
  Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
- 2024-03-05
  Beneficial Ownership Change
  Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
  Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]

1D
5D
Day
Week
Month

Loading ...

High

3.21

Open

2.98

Volume%

1.45

Low

2.90

T/O Rate

5.81%

抱歉，当前请求异常(-1)

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

To The Moon

Absci Corporation.(ABSI)

Absci (NASDAQ:ABSI) reports Q1 financial results, alongside advances in drug development

MRNA, SDGR, ABSI, EXAI & RXRX Work with AI Companies to Accelerate Drug Development

Company Profile